Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$13.98 USD
-0.10 (-0.71%)
Updated May 3, 2024 04:00 PM ET
After-Market: $13.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TEVA 13.98 -0.10(-0.71%)
Will TEVA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Other News for TEVA
Earnings week ahead: Disney, Palantir, Shopify, Uber, Plug Power and more
16 out of 24 health care companies beat topline numbers this week- Earnings scorecard
Teva to Present at the 2024 Bank of America Healthcare Conference
Exelixis: With Patent Litigation Decision Due Soon, There Are Options
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets